James S. Economou

James S. Economou

Auto-generated profile, based on publicly available information

James S. Economou

University of California, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003
Verified
Journal Article
Closed access
LBLisa H Butterfield
Lisa H Butterfield
ARAntoni Ribas
Antoni Ribas
VDVivian B Dissette
Vivian B Dissette
SASaral N Amarnani
Saral N Amarnani
HVHuong T Vu
Huong T Vu
JEJames S Economou
James S Economou

1 May 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
BCBegoña Comin-Anduix
Begoña Comin-Anduix
YLYohan Lee
Yohan Lee
JJJason Jalil
Jason Jalil
AAAlain Algazi
Alain Algazi
PRPilar de la Rocha
Pilar de la Rocha
ARAntoni Ribas
Antoni Ribas
Background: CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated. Methods: Peripheral blood from HLA-A*0201-positive patients with advanced melanoma receiving tremelimumab (formerly CP-675,206) at 10 mg/kg monthly was repeatedly sampled during the first 4 cycles. Samples were analyzed by 1) tetramer and ELISPOT assays for reactivity to CMV, EBV, MART1, gp100, and tyrosinase; 2) activation HLA-DR and memory CD45RO markers on CD4+/CD8+ cells; and 3) real-time quantitative PCR of mRNA for FoxP3 transcription factor, preferentially expressed by T regulatory cells. The primary endpoint was difference in MART1-specific T cells by tetramer assay. Immunological data were explored for significant trends using clustering analysis. Results: Three of 12 patients eligible for immune monitoring had tumor regression lasting > 2 years without relapse. There was no significant change in percent of MART1-specific T cells by tetramer assay. Additionally, there was no generalized trend toward postdosing changes in other antigen-specific CD8+ cell populations, FoxP3 transcripts, or overall changes in surface expression of T-cell activation or memory markers. Unsupervised hierarchical clustering based on immune monitoring data segregated patients randomly. However, clustering according to T-cell activation or memory markers separated patients with clinical response and most patients with inflammatory toxicity into a common subgroup. Conclusion: Administration of CTLA4-blocking antibody tremelimumab to patients with advanced melanoma results in a subset of patients with long-lived tumor responses. T-cell activation and memory markers served as the only readout of the pharmacodynamic effects of this antibody in peripheral blood. Clinical trial registration number: NCT00086489

1 December 2003
Verified
Journal Article
Closed access
LBLisa H Butterfield
Lisa H Butterfield
ARAntoni Ribas
Antoni Ribas
WMWilson S Meng
Wilson S Meng
VDVivian B Dissette
Vivian B Dissette
SASaraL Amarnani
SaraL Amarnani
JEJames S Economou
James S Economou

19 June 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JQJon G Quatromoni
Jon G Quatromoni
YWYue Wang
Yue Wang
DVDan D Vo
Dan D Vo
LMLilah F Morris
Lilah F Morris
AJAli R. Jazirehi
Ali R. Jazirehi
JEJames S Economou
James S Economou
Tumor antigen-reactive T cells must enter into an immunosuppressive tumor microenvironment, continue to produce cytokine and deliver apoptotic death signals to affect tumor regression. Many tumors produce transforming growth factor beta (TGFβ), which inhibits T cell activation, proliferation and cytotoxicity. In a murine model of adoptive cell therapy, we demonstrate that transgenic Pmel-1 CD8 T cells, rendered insensitive to TGFβ by transduction with a TGFβ dominant negative receptor II (DN), were more effective in mediating regression of established B16 melanoma. Smaller numbers of DN Pmel-1 T cells effectively mediated tumor regression and retained the ability to produce interferon-γ in the tumor microenvironment. These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer.

5 April 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HPHelicia Paz
Helicia Paz
JTJennifer Tsoi
Jennifer Tsoi
AKAnusha Kalbasi
Anusha Kalbasi
CGCatherine S. Grasso
Catherine S. Grasso
WMWilliam McBride
William McBride
JEJames S. Economou
James S. Economou
Various proinflammatory cytokines can be detected within the melanoma tumor microenvironment. Interleukin 32 (IL32) is produced by T cells, NK cells and monocytes/macrophages, but also by a subset of melanoma cells. We sought to better understand the biology of IL32 in human melanoma. We analyzed RNA sequencing data from 53 in-house established human melanoma cell lines and 479 melanoma tumors from The Cancer Genome Atlas dataset. We evaluated global gene expression patterns associated with IL32 expression. We also evaluated the impact of proinflammatory molecules TNFα and IFNγ on IL32 expression and dedifferentiation in melanoma cell lines in vitro. In order to study the transcriptional regulation of IL32 in these cell lines, we cloned up to 10.5 kb of the 5′ upstream region of the human IL32 gene into a luciferase reporter vector. A significant proportion of established human melanoma cell lines express IL32, with its expression being highly correlated with a dedifferentiation genetic signature (high AXL/low MITF). Non IL32-expressing differentiated melanoma cell lines exposed to TNFα or IFNγ can be induced to express the three predominant isoforms (α, β, γ) of IL32. Cis-acting elements within this 5′ upstream region of the human IL32 gene appear to govern both induced and constitutive gene expression. In the tumor microenvironment, IL32 expression is highly correlated with genes related to T cell infiltration, and also positively correlates with high AXL/low MITF dedifferentiated gene signature. Expression of IL32 in human melanoma can be induced by TNFα or IFNγ and correlates with a treatment-resistant dedifferentiated genetic signature. Constitutive and induced expression are regulated, in part, by cis-acting sequences within the 5′ upstream region.

18 October 2002 in Cancer Gene Therapy
Verified
Journal Article
Closed access
ARAntoni Ribas
Antoni Ribas
SASaral N Amarnani
Saral N Amarnani
GBGeorgette M Buga
Georgette M Buga
LBLisa H Butterfield
Lisa H Butterfield
VDVivian B Dissette
Vivian B Dissette
JEJames S Economou
James S Economou